"he strengths and challenges outlined below are initial findings from a longer working paper developed to analyze the current global situation of each product. The findings are presented below to catalyze further thinking and discussion in order to finalize a list of issues and recommendations. The full working paper texts are forthcoming."
काठमाडौ, पुस २५ – नवजात शिशुको नाइटोमा हुने संक्रमण रोक्न नेपालले विकास गरेको किटनाशक औषधिले अमेरिकी सहयोग नियोगको विज्ञान तथा प्रविधि पुरस्कार पाएको छ ।
क्लोरहेक्सिडाइन डाइग्लुकोनेट सिएचएक्स मल्हमको अनुसन्धानले प्रभावकारी नतिजा निकालेको ठहर गर्दै प्रविधिका लागि युएसएडको विज्ञान तथा प्रविधि नव सिर्जना पुरस्कार प्रदान गरिएको हो ।
यो मल्हम नेपालको औषधि निर्माता कम्पनी लोमस फर्म्यसुटिकल्सले उत्पादन गरेको हो । युएसएडले हरेक वर्ष विकासका चुनौतीलाई विज्ञान, प्रविधि तथा नव प्रवर्तनको प्रयोग गरी समाधान गर्ने उत्कृष्ट प्रविधिलाई सम्मान गर्दै आएको छ । शिशुमा नाइटोको संक्रमण रोक्न प्रयोग हुने किटनाशक मल्हम सिएचएक्सको प्रयोगबाट नेपालमा नवजात शिशुमृत्युदर ३४ प्रतिशतले घटेको छ ।
यो मल्हम प्रभावकारी हुनुका साथै सस्तो पनि छ । राष्ट्रिय स्वास्थ्य इन्ष्टिच्युट र विल तथा मेलिन्डा गेट्स प्रतिष्ठानसँगको सहकार्यमा युएसएडले सिएच एक्सलाई पहिले झोलका रुपमा र पछि जेलका रुपमा परीक्षण गरेको थियो । यो मल्हमलाई एकपटक मात्र नवजात शिशुको
नालमा लगाउँदा संक्रमणको खतरा निकै कम हुने गरेको पाइएको छ ।
किटनाशक जेल यो वर्षको अन्त्यसम्म नेपालका अधिकांश जिल्लामा पु¥याउने लक्ष्य छ । यसको प्रयोगले नवजात शिशुको मृत्युदर घटाएर राखिएको लक्ष्य सजिलै हाँसिल गर्न सकिने अपेक्षा गरिएको छ ।
पछिल्लो तथ्यांक अनुसार नेपालमा १ सय जना नवजात शिशुमध्ये ३ जनाले नाइटोको संक्रमणका कारण २८ दिनभित्र ज्यान गुमाउने गरेका थिए । यो मल्हम नाइजेरियाले पनि परीक्षण गर्ने योजना बनाएको छ ।
Globally, neonatal sepsis accounts for over 500,000 newborn deaths annually1. Many of these infections come from contamination of the umbilical cord stump. Chlorhexidine (CHX) digluconate is a widely used, low-cost antiseptic effective against major agents of neonatal infection. Since its introduction in the 1950s, it has been used regularly as a surgical, veterinary, neonatal and
dental antiseptic and carefully studied for safety and efficacy. Recent community-level randomized controlled trials in Nepal2, Pakistan3,4, and Bangladesh3,4 have shown that applying a 4% CHX product (7.1% CHX digluconate) to the umbilical cord saves lives. Across the three countries, data from over 54,000 newborns showed an aggregate 23% reduction in neonatal mortality (not including deaths in the first few hours of life) and a 68% reduction in severe infections for the CHX intervention groups2,3,4. The results are some of the largest effect sizes seen in any neonatal intervention. CHX has a long shelf life, requires no cold chain, and is extremely easy to apply with minimal training and no equipment. These factors make it suitable for hospital, health center, and home care alike. Few other interventions have demonstrated such potential for rapidly reducing newborn mortality across so many settings for such a low cost. Action is necessary to prioritize increased use of this overlooked intervention, thereby contributing to hundreds of thousands of newborn lives saved annually.
Chlorhexidine (CHX) product characteristics:
| Drug: | Chlorhexidine gluconate (also called Chlorhexidine digluconate or just Chlorhexidine) |
| Proposed Indication: | Antiseptic for umbilical cord care/cleansing |
| Formulation: | 7.1% CHX digluconate aqueous solution or gel, delivering 4% CHX for umbilical cord care |
| Dose: | 3 grams for single day application (as currently practiced in Nepal) |
| Avg. Cost: | Around $0.30 (as currently sold in Nepal)5 |
Initial Findings from Product Case Study Working Paper
* Note: The strengths and challenges outlined below are initial findings from a longer working paper developed to analyze the current global situation of each product. The findings are presented below to catalyze further thinking and discussion in order to finalize a list of issues and recommendations. The full working paper texts are forthcoming.
